Immune System News and Research

RSS

Qigong and Tai Chi offer physical and mental health benefits

An across-the-board review of the health effects of Qigong and Tai Chi finds these practices offer many physical and mental health advantages with benefits for the heart, immune system and overall quality of life.

30 Jun 2010

Original viral genetic sequences still present months after initial infection, says study

Scientists have been surprised to learn that, despite thousands of changes that viruses like HIV undergo in rapid fashion to evade the body's immune system, the original version that caused the infection is still present in the body months later.

30 Jun 2010

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Individual cells react differently to complex signals: Study

Using new technology that allows scientists to monitor how individual cells react in the complex system of cell signaling, Stanford University researchers have uncovered a much larger spectrum of differences between each cell than ever seen before.

29 Jun 2010

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

Scientists have discovered that when they transplant ovaries from young mice into aging female mice, not only does the procedure make the mice fertile again, but also it rejuvenates their behaviour and increases their lifespan. The question now is: could ovarian transplants in women have the same effect?

29 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

Rare human antibodies protect mice from lethal strains of influenza

Scientists have identified a new, highly conserved molecular target on the influenza A virus and demonstrated that human antibodies against this target are protective in animal models of seasonal and highly-pathogenic avian influenza. The work was conducted by researchers at Theraclone Sciences, with collaborators at University of Wisconsin-Madison, University of Tokyo and Johns Hopkins University; and is reported this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

29 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

Researchers use neonatal piglet model to study infant brain development

Events occurring during the development of an infant's brain can leave behind fingerprints. And researchers at the University of Illinois are interested in learning how these fingerprints can predict future behavioral problems such as cognitive deficits, anxiety disorders, depression, and even autism.

29 Jun 2010

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

29 Jun 2010

MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes

Massachusetts General Hospital (MGH) and the Iacocca Foundation announce today the completion of the Phase I BCG clinical trial in type 1 diabetes, as well as the submission of all safety reports to the U.S. Food and Drug Administration (FDA) and the MGH data safety monitoring boards. Plans for the Phase II clinical study, which will continue the investigation of bacillus Calmette-Guerin (BCG) vaccination as a treatment for people with existing type 1 diabetes, are actively underway.

29 Jun 2010

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Vietnam War-era veterans exposed to Agent Orange appear to have significantly more Graves' disease, a thyroid disorder, than veterans with no exposure, a new study by endocrinologists at the University at Buffalo has shown.

29 Jun 2010

Cancer clues from pregnant lizards

A compound produced by a pregnant lizard may provide important information on the origins and treatment of cancer in humans, according to zoologist Bridget Murphy from the School of Biological Sciences who discovered the protein, which is pivotal to the development of the lizard placenta.

28 Jun 2010

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

The International AIDS Vaccine Initiative (IAVI) announced today that the Government of Japan pledged a US$10 million grant to support AIDS vaccine research and development over the next five years. The grant, which will be channeled through a newly established World Bank trust fund, is the first of its kind from the Japanese government to IAVI.

28 Jun 2010

Cells in immune system react to stomach ulcer bacterium Helicobacter pylori, identify researchers

Researchers have identified cells in the immune system that react to the stomach ulcer bacterium Helicobacter pylori, one of the risk factors for the development of stomach cancer. This discovery could lead to faster diagnosis and treatment as well as a better prognosis for patients with stomach cancer, reveals a thesis from the University of Gothenburg, Sweden.

28 Jun 2010

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.

28 Jun 2010

TRL commences operations at San Diego facility with focus on biological drugs for autoimmune diseases

Tanabe Research Labs USA, Inc. (TRL) today announced commencement of its new operations at the TRL facility in San Diego with a focus on biological drugs for the treatment of autoimmune diseases. TRL began its new activities in May with the appointment of three new senior executives: Masaki Yamada, Ph.D., Chief Executive Officer; Toshihiro Hosaka, Ph.D., Senior Vice President, and Roland Newman, Ph.D., VP and Chief Scientific Officer.

28 Jun 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Human Genome Sciences, Inc. today announced the presentation of additional results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26.

28 Jun 2010

Immune System News and Research

Qigong and Tai Chi offer physical and mental health benefits

Original viral genetic sequences still present months after initial infection, says study

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

BBD reports analyze effectiveness and safety of statin use

Individual cells react differently to complex signals: Study

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

Rare human antibodies protect mice from lethal strains of influenza

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Researchers use neonatal piglet model to study infant brain development

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Cancer clues from pregnant lizards

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

Cells in immune system react to stomach ulcer bacterium Helicobacter pylori, identify researchers

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

TRL commences operations at San Diego facility with focus on biological drugs for autoimmune diseases

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News